- Main
An open-label, single-arm pilot study of EUS-guided brachytherapy with phosphorus-32 microparticles in combination with gemcitabine +/- nab-paclitaxel in unresectable locally advanced pancreatic cancer (OncoPaC-1): Technical details and study protocol
- Bhutani, Manoop S;
- Klapman, Jason B;
- Tuli, Richard;
- El-Haddad, Ghassan;
- Hoffe, Sarah;
- Wong, Franklin CL;
- Chasen, Beth;
- Fogelman, David R;
- Lo, Simon K;
- Nissen, Nicholas N;
- Hendifar, Andrew E;
- Varadhachary, Gauri;
- Katz, Matthew HG;
- Erwin, William D;
- Koay, Eugene J;
- Tamm, Eric P;
- Singh, Ben S;
- Mehta, Rutika;
- Wolff, Robert A;
- Soman, Ashish;
- Cazacu, Irina M;
- Herman, Joseph M
- et al.
Published Web Location
https://doi.org/10.4103/eus.eus_44_19Abstract
Current treatment options for patients with unresectable locally advanced pancreatic cancer (LAPC) include chemotherapy alone or followed by chemoradiation or stereotactic body radiotherapy. However, the prognosis for these patients remains poor, with a median overall survival <12 months. Therefore, novel treatment options are needed. Currently, there is no brachytherapy device approved for pancreatic cancer treatment. Hereby, we present the protocol of a prospective, multicenter, interventional, open-label, single-arm pilot study (OncoPac-1, Clinicaltrial.gov-NCT03076216) aiming to determine the safety and efficacy of Phosphorus-32 when implanted directly into pancreatic tumors using EUS guidance, for patients with unresectable LAPC undergoing chemotherapy (gemcitabine ± nab-paclitaxel).
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.
Main Content
Enter the password to open this PDF file:
-
-
-
-
-
-
-
-
-
-
-
-
-
-